Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + sorafenib
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Erlotinib + sorafenib is a combination of two oral small molecule kinase inhibitors used in clinical trials for the treatment of various solid tumors, including recurrent glioblastoma and advanced pancreatic cancer. Erlotinib acts as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, blocking EGFR-mediated signaling pathways involved in tumor cell proliferation. Sorafenib inhibits multiple kinases, including RAF kinases in the Ras/Raf/MEK/ERK pathway and receptor tyrosine kinases such as VEGFR and PDGFR, thereby inhibiting both tumor cell proliferation and angiogenesis. The combination has been studied to target complementary pathways involved in cancer progression but has shown limited efficacy with notable toxicity risks[1][2][5][6].
- Brand names
- Tarceva (for erlotinib)Nexavar (for sorafenib)
- Other names
- erlotinib + sorafenib
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)CYP1A1 (Cytochrome P450 1A1)DDR1 (Discoidin domain receptor 1)EGFR (Epidermal growth factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on erlotinib + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + sorafenib.